Geron reports real-world RYTELO study shows 37.5% transfusion independence in lower-risk MDS

• Geron flagged first real-world evidence study of its anemia drug RYTELO (imetelstat) in lower-risk myelodysplastic syndromes for presentation at European Hematology Association Congress 2026, with retrospective data slated for Jun 12.
• Study from Moffitt Cancer Center reported safety and clinical benefit broadly consistent with Phase 3 IMerge results in a broader, heavily pretreated patient group, including patients previously treated with multiple therapies.
• Analysis pointed to durable relief from transfusion burden in a subset of patients, with several responses ongoing at time of review.
• Adverse events were led by low blood counts, aligning with known risks for imetelstat.
• Geron also outlined additional 2026 conference disclosures tied to imetelstat programs in myelofibrosis and relapsed acute myeloid leukemia, including updated survival comparisons versus real-world data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120931PRIMZONEFULLFEED9718369) on May 12, 2026, and is solely responsible for the information contained therein.